News

On the surface, Pfizer (NYSE: PFE) had some good news to report on Thursday. But investors viewed the positive as a negative, in light of its timing. This wasn't helped by an analyst's price-target

Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. I'm talking about Novavax

Pfizer (NYSE: PFE) has been a losing play for investors over the past 12 months. To wit: The drugmaker's stock has fallen by a whopping 28.8% over this period. Part of that decline has been driven

Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that

Telecom giant AT&T (NYSE: T) has a very simple story now that it's shed its ambitions to become a media conglomerate. The core business is wireless, which will grow slowly at best. The secondary

Shares of Sarepta Therapeutics (NASDAQ: SRPT), which focuses on genetic treatments for rare diseases, were down 11.5% Wednesday afternoon after the Food and Drug Administration (FDA) pushed back its

Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key

There are reasons to be wary of the stock market right now. Chief among them is the fact that the economy continues to be somewhat uncertain, making it difficult to predict how things will develop

The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between

Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong

Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight

The various market indexes are all positive so far in 2023, but the rebound is not universal and there's no shortage of stocks still trading near their lows. A couple of struggling stocks that

Catalent (NYSE: CTLT) investors are clearly an optimistic bunch, as lately they've been taking not-so-bad-news very positively and trading up the stock. This dynamic was clearly in force on Monday

Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is

Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43

Equities experienced a bear market in 2022, and although things have improved significantly over the past few months, it's impossible to say whether we are out of the woods. However, some

Buying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the

Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was